IP Library Granted Patent US 10,308,676
Granted Patent B2
US 10,308,676 · App. 15/274,555 · Granted Jun 4, 2019

Methods of making onapristone intermediates

Inventors: Ulf Tilstam (Hoegaarden, BE); Stefan Proniuk (Austin, TX); Holger Bindernagel (Gelnhausen, DE); Silvia Werner (Kahl, DE); Holger Rauter (Flieden, DE)
Assignee: CONTEXT BIOPHARMA INC.
C07J33/005C07J41/0083
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,676
App. No.
15/274,555
Granted
Jun 4, 2019
Kind
B2
Abstract

Methods and systems for making intermediates in the synthesis of onapristone are provided. Aspects include the photoconversion of onapristone synthesis intermediates using a narrow band frequency light source.

Claims (22)

1. A method of making the compound of Formula II

comprising irradiating the compound of Formula I

with narrow band frequency light from a lamp selected from the group consisting of excimer DBD light source and LED at a wavelength from about 295 nm to about 320 nm;

wherein taken together the two instances of X combine to form a spirocyclic ring of the formula of —OCH 2 CH 2 O— or —OCH 2 C(Me) 2 CH 2 O—.

2. The method of claim 1 , wherein the wavelength of narrow band frequency light is about 308 nm from a DBD light source.

3. The method of claim 1 , wherein the lamp is a DBD light source.

4. The method of claim 1 , wherein the ratio of Formula I to Formula II is about 20:80.

5. A method of making Steroid 2:

comprising irradiating the compound of Formula I

with narrow band frequency light from a lamp selected from the group consisting of excimer DBD light source and LED, at a wavelength from about 295 nm to about 320 nm.

6. The method of claim 5 , wherein the wavelength of narrow band frequency light is about 308 nm.

7. The method of claim 5 , wherein the lamp is an excimer lamp.

8. The method of claim 5 , wherein the ratio of Formula I to Steroid 2 is about 5-10:90-95%.

9. A method of making the compound of Formula II

comprising irradiating the compound of Formula I

with narrow band frequency light from a lamp selected from the group consisting of excimer DBD light source and LED at a wavelength from about 295 nm to about 320 nm;

wherein X is selected from the group consisting of OMe, OEt, and OPr.

10. The method of claim 9 , wherein the wavelength of narrow band frequency light is about 308 nm.

11. The method of claim 9 , wherein the lamp is an excimer lamp.

12. The method of claim 9 , wherein X is OMe.

13. The method of claim 9 , wherein X is OEt.

14. The method of claim 9 , wherein X is OPr.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2021
From: LEHR, SETH
To: CONTEXT BIOPHARMA, INC.
Reel/Frame 055560/0750 →
SECURITY INTEREST Recorded Apr 2, 2020
From: CONTEXT BIOPHARMA, INC.
To: LEHR, SETH
Reel/Frame 052293/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2018
From: ARNO THERAPEUTICS, INC.
To: CONTEXT BIOPHARMA INC.
Reel/Frame 044769/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: TILSTAM, ULF; PRONIUK, STEFAN; BINDERNAGEL, HOLGER; WERNER, SILVIA; RAUTER, HOLGER
To: ARNO THERAPEUTICS, INC.
Reel/Frame 043001/0909 →
Continuity (2)
Provisional Application 62233166 · Sep 25, 2015
Related Publication 20170088579A1 · Mar 30, 2017